In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients

Transplantation Proceedings

Volumn 28, Issue 2, 1996, Pages 915-916

  Stock, P G ^a   Lantz, M ^a   Light, S ^a   Vincenti, F ^a  

^a UCSF Medical Center at Parnassus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; STEROID;

ANTIBODY PRODUCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MIXED LYMPHOCYTE CULTURE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LYMPHOCYTE CULTURE TEST, MIXED; RECEPTORS, INTERLEUKIN-2;

EID: 0029993752     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)